<H1>Chapter DOI: 10.1007/s00105-015-3656-3<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>82</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>80</td></tr><tr><td>BibStructured Count</td><td width="10%">0</td></tr><tr><td>BibUnstructured Count</td><td width="10%">82</td></tr><tr><td>DOI already available in SpringerLink</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>67</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>3</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>69</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>-1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>71</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ahmed</span> <span style='background:#DDDDDD'>AR</span></span></aug> (<span style='background:#66FF66'>2001</span>) <span style='background:#CCCCFF'>Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment</span>. <span style='background:#CCFF99'>J Am Acad Dermatol</span> <span style='background:#FFCC66'>45</span>:<span style='background:#D279FF'>679&#8211;690</span></td><td><a href=http://dx.doi.org/10.1067/mjd.2001.116339>10.1067/mjd.2001.116339</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR2</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ahmed</span> <span style='background:#DDDDDD'>AR</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Spigelman</span> <span style='background:#DDDDDD'>Z</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Cavacini</span> <span style='background:#DDDDDD'>LA</span></span> et al</aug> (<span style='background:#66FF66'>2006</span>) <span style='background:#CCCCFF'>Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin</span>. <span style='background:#CCFF99'>N Engl J Med</span> <span style='background:#FFCC66'>355</span>:<span style='background:#D279FF'>1772&#8211;1779</span></td><td><a href=http://dx.doi.org/10.1056/NEJMoa062930>10.1056/NEJMoa062930</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR3</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Amagai</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ikeda</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Shimizu</span> <span style='background:#DDDDDD'>H</span></span> et al</aug> (<span style='background:#66FF66'>2009</span>) <span style='background:#CCCCFF'>A randomized double-blind trial of intravenous immunoglobulin for pemphigus</span>. <span style='background:#CCFF99'>J Am Acad Dermatol</span> <span style='background:#FFCC66'>60</span>:<span style='background:#D279FF'>595&#8211;603</span></td><td><a href=http://dx.doi.org/10.1016/j.jaad.2008.09.052>10.1016/j.jaad.2008.09.052</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, VolumeID, Author_FamilyName_2, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR4</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Amagai</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Komai</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hashimoto</span> <span style='background:#DDDDDD'>T</span></span> et al</aug> (<span style='background:#66FF66'>1999</span>) <span style='background:#CCCCFF'>Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus</span>. <span style='background:#CCFF99'>Br J Dermatol</span> <span style='background:#FFCC66'>140</span>:<span style='background:#D279FF'>351&#8211;357</span></td><td><a href=http://dx.doi.org/10.1046/j.1365-2133.1999.02752.x>10.1046/j.1365-2133.1999.02752.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, VolumeID, Author_FamilyName_2, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Amber</span> <span style='background:#DDDDDD'>KT</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Staropoli</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Shiman</span> <span style='background:#DDDDDD'>MI</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris</span>. <span style='background:#CCFF99'>Exp Dermatol</span> <span style='background:#FFCC66'>22</span>:<span style='background:#D279FF'>699&#8211;704</span></td><td><a href=http://dx.doi.org/10.1111/exd.12229>10.1111/exd.12229</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, VolumeID, Author_FamilyName_2, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR6</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Anhalt</span> <span style='background:#DDDDDD'>GJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Labib</span> <span style='background:#DDDDDD'>RS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Voorhees</span> <span style='background:#DDDDDD'>JJ</span></span> et al</aug> (<span style='background:#66FF66'>1982</span>) <span style='background:#CCCCFF'>Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease</span>. <span style='background:#CCFF99'>N Engl J Med</span> <span style='background:#FFCC66'>306</span>:<span style='background:#D279FF'>1189&#8211;1196</span></td><td><a href=http://dx.doi.org/10.1056/NEJM198205203062001>10.1056/NEJM198205203062001</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, FirstPage, Year, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR7</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Antoniu</span> <span style='background:#DDDDDD'>S</span></span></aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Epratuzumab for systemic lupus erythematosus</span>. <span style='background:#CCFF99'>Expert Opin Biol Ther</span> <span style='background:#FFCC66'>14</span>:<span style='background:#D279FF'>1045&#8211;1047</span></td><td><a href=http://dx.doi.org/10.1517/14712598.2014.915937>10.1517/14712598.2014.915937</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR8</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Arin</span> <span style='background:#DDDDDD'>MJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Engert</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Krieg</span> <span style='background:#DDDDDD'>T</span></span> et al</aug> (<span style='background:#66FF66'>2005</span>) <span style='background:#CCCCFF'>Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus</span>. <span style='background:#CCFF99'>Br J Dermatol</span> <span style='background:#FFCC66'>153</span>:<span style='background:#D279FF'>620&#8211;625</span></td><td><a href=http://dx.doi.org/10.1111/j.1365-2133.2005.06651.x>10.1111/j.1365-2133.2005.06651.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, FirstPage, Year, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR9</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Balighi</span> <span style='background:#DDDDDD'>K</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Daneshpazhooh</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Khezri</span> <span style='background:#DDDDDD'>S</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial</span>. <span style='background:#CCFF99'>Int J Dermatol</span> <span style='background:#FFCC66'>52</span>:<span style='background:#D279FF'>862&#8211;867</span></td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1111/j.1365-4632.2012.5847.x>10.1111/j.1365-4632.2012.5847.x</a></td><td><b>CrossRef-Web</b></td>
<td>FirstPage, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR10</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Beck</span> <span style='background:#DDDDDD'>LA</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Thaci</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hamilton</span> <span style='background:#DDDDDD'>JD</span></span> et al</aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Dupilumab treatment in adults with moderate-to-severe atopic dermatitis</span>. <span style='background:#CCFF99'>N Engl J Med</span> <span style='background:#FFCC66'>371</span>:<span style='background:#D279FF'>130&#8211;139</span></td><td><a href=http://dx.doi.org/10.1056/NEJMoa1314768>10.1056/NEJMoa1314768</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Borradori</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lombardi</span> <span style='background:#DDDDDD'>T</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Samson</span> <span style='background:#DDDDDD'>J</span></span> et al</aug> (<span style='background:#66FF66'>2001</span>) <span style='background:#CCCCFF'>Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus</span>. <span style='background:#CCFF99'>Arch Dermatol</span> <span style='background:#FFCC66'>137</span>:<span style='background:#D279FF'>269&#8211;272</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bystryn</span> <span style='background:#DDDDDD'>JC</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Rudolph</span> <span style='background:#DDDDDD'>JL</span></span></aug> (<span style='background:#66FF66'>2005</span>) <span style='background:#CCCCFF'>Pemphigus</span>. <span style='background:#CCFF99'>Lancet</span> <span style='background:#FFCC66'>366</span>:<span style='background:#D279FF'>61&#8211;73</span></td><td><a href=http://dx.doi.org/10.1016/S0140-6736(05)66829-8>10.1016/S0140-6736(05)66829-8</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Year, FirstPage, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR13</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Calabresi</span> <span style='background:#DDDDDD'>PA</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Radue</span> <span style='background:#DDDDDD'>EW</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Goodin</span> <span style='background:#DDDDDD'>D</span></span> et al</aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Safety and efficacy of fingolimod in patients with relapsingremitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial</span>. <span style='background:#CCFF99'>Lancet Neurol</span> <span style='background:#FFCC66'>13</span>:<span style='background:#D279FF'>545&#8211;556</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Colliou</span> <span style='background:#DDDDDD'>N</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Picard</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Caillot</span> <span style='background:#DDDDDD'>F</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response</span>. <span style='background:#CCFF99'>Sci Transl Med</span> 5:175ra130</td><td><a href=http://dx.doi.org/10.1126/scitranslmed.3005166>10.1126/scitranslmed.3005166</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR15</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Czernik</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Toosi</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bystryn</span> <span style='background:#DDDDDD'>JC</span></span> et al</aug> (<span style='background:#66FF66'>2012</span>) <span style='background:#CCCCFF'>Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update</span>. <span style='background:#CCFF99'>Autoimmunity</span> <span style='background:#FFCC66'>45</span>:<span style='background:#D279FF'>111&#8211;118</span></td><td><a href=http://dx.doi.org/10.3109/08916934.2011.606452>10.3109/08916934.2011.606452</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, JournalTitle, VolumeID, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR16</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Elhai</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Meunier</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Matucci-Cerinic</span> <span style='background:#DDDDDD'>M</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study</span>. <span style='background:#CCFF99'>Ann Rheum Dis</span> <span style='background:#FFCC66'>72</span>:<span style='background:#D279FF'>1217&#8211;1220</span></td><td><a href=http://dx.doi.org/10.1136/annrheumdis-2012-202657>10.1136/annrheumdis-2012-202657</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, FirstPage, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR17</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ellebrecht</span> <span style='background:#DDDDDD'>CT</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Choi</span> <span style='background:#DDDDDD'>EJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Allman</span> <span style='background:#DDDDDD'>DM</span></span> et al</aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris</span>. <span style='background:#CCFF99'>JAMA Dermatol</span> <span style='background:#FFCC66'>150</span>:<span style='background:#D279FF'>1331&#8211;1335</span></td><td><a href=http://dx.doi.org/10.1001/jamadermatol.2014.1939>10.1001/jamadermatol.2014.1939</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, JournalTitle, ArticleTitle, Author_FamilyName_2, VolumeID, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR18</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Emery</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Burmester</span> <span style='background:#DDDDDD'>GR</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bykerk</span> <span style='background:#DDDDDD'>VP</span></span> et al</aug> (<span style='background:#66FF66'>2015</span>) <span style='background:#CCCCFF'>Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period</span>. <span style='background:#CCFF99'>Ann Rheum Dis</span> <span style='background:#FFCC66'>74</span>:<span style='background:#D279FF'>19&#8211;26</span></td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1136/annrheumdis-2014-206106>10.1136/annrheumdis-2014-206106</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR19</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hertl</span> <span style='background:#DDDDDD'>M</span></span></aug> (<span style='background:#66FF66'>2006</span>) <span style='background:#CCCCFF'>Immunoadsorption in pemphigus</span>. <span style='background:#CCFF99'>Autoimmunity</span> <span style='background:#FFCC66'>39</span>:<span style='background:#D279FF'>609&#8211;616</span></td><td><a href=http://dx.doi.org/10.1080/08916930600972040>10.1080/08916930600972040</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, ArticleTitle, Author_FamilyName_2, VolumeID, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR20</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Nagel</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wolff-Franke</span> <span style='background:#DDDDDD'>S</span></span> et al</aug> (<span style='background:#66FF66'>2008</span>) <span style='background:#CCCCFF'>Rituximab exerts a dual effect in Pemphigus vulgaris</span>. <span style='background:#CCFF99'>J Invest Dermatol</span> <span style='background:#FFCC66'>128</span>(<span style='background:#C8BE84'>12</span>):<span style='background:#D279FF'>2850&#8211;2858</span></td><td><a href=http://dx.doi.org/10.1038/jid.2008.172>10.1038/jid.2008.172</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, VolumeID, Author_FamilyName_2, FirstPage, Year, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR21</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Rech</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Barth</span> <span style='background:#DDDDDD'>S</span></span> et al</aug> (<span style='background:#66FF66'>2006</span>) <span style='background:#CCCCFF'>Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption</span>. <span style='background:#CCFF99'>Dermatology</span> <span style='background:#FFCC66'>212</span>:<span style='background:#D279FF'>177&#8211;187</span></td><td><a href=http://dx.doi.org/10.1159/000090659>10.1159/000090659</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR22</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Faurschou</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Jayne</span> <span style='background:#DDDDDD'>DR</span></span></aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Anti-B cell antibody therapies for inflammatory rheumatic diseases</span>. <span style='background:#CCFF99'>Annu Rev Med</span> <span style='background:#FFCC66'>65</span>:<span style='background:#D279FF'>263&#8211;278</span></td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1146/annurev-med-070912-133235>10.1146/annurev-med-070912-133235</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Year, FirstPage, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR23</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Feliciani</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Toto</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Amerio</span> <span style='background:#DDDDDD'>P</span></span> et al</aug> (<span style='background:#66FF66'>2000</span>) <span style='background:#CCCCFF'>In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis</span>. <span style='background:#CCFF99'>J Invest Dermatol</span> <span style='background:#FFCC66'>114</span>:<span style='background:#D279FF'>71&#8211;77</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Feliciani</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Toto</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wang</span> <span style='background:#DDDDDD'>B</span></span> et al</aug> (<span style='background:#66FF66'>2003</span>) <span style='background:#CCCCFF'>Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis</span>. <span style='background:#CCFF99'>Exp Dermatol</span> <span style='background:#FFCC66'>12</span>:<span style='background:#D279FF'>466&#8211;471</span></td><td><a href=http://dx.doi.org/10.1034/j.1600-0625.2002.120415.x>10.1034/j.1600-0625.2002.120415.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR25</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Furie</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Petri</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Zamani</span> <span style='background:#DDDDDD'>O</span></span> et al</aug> (<span style='background:#66FF66'>2011</span>) <span style='background:#CCCCFF'>A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulators, in patients with systemic lupus erythematosus</span>. <span style='background:#CCFF99'>Arthritis Rheum</span> <span style='background:#FFCC66'>63</span>:<span style='background:#D279FF'>3918&#8211;3930</span></td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/art.30613>10.1002/art.30613</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, VolumeID, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR26</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Genovese</span> <span style='background:#DDDDDD'>MC</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kinnman</span> <span style='background:#DDDDDD'>N</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#FFFF80'>de</span> <span style='background:#BCBCBC'>La Bourdonnaye</span> <span style='background:#DDDDDD'>G</span></span> et al</aug> (<span style='background:#66FF66'>2011</span>) <span style='background:#CCCCFF'>Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase II, randomized, placebo-controlled, dose-finding trial</span>. <span style='background:#CCFF99'>Arthritis Rheum</span> <span style='background:#FFCC66'>63</span>:<span style='background:#D279FF'>1793&#8211;1803</span></td><td><a href=http://dx.doi.org/10.1002/art.30373>10.1002/art.30373</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, FirstPage, Year, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR27</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ginzler</span> <span style='background:#DDDDDD'>EM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wax</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Rajeswaran</span> <span style='background:#DDDDDD'>A</span></span> et al</aug> (<span style='background:#66FF66'>2012</span>) <span style='background:#CCCCFF'>Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial</span>. <span style='background:#CCFF99'>Arthritis Res Ther</span> 14:R33</td><td><a href=http://dx.doi.org/10.1186/ar3738>10.1186/ar3738</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, ArticleTitle, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR28</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gong</span> <span style='background:#DDDDDD'>Q</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ou</span> <span style='background:#DDDDDD'>Q</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ye</span> <span style='background:#DDDDDD'>S</span></span> et al</aug> (<span style='background:#66FF66'>2005</span>) <span style='background:#CCCCFF'>Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy</span>. <span style='background:#CCFF99'>J Immunol</span> <span style='background:#FFCC66'>174</span>:<span style='background:#D279FF'>817&#8211;826</span></td><td><a href=http://dx.doi.org/10.4049/jimmunol.174.2.817>10.4049/jimmunol.174.2.817</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, VolumeID, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR29</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hall</span> <span style='background:#DDDDDD'>RP</span> <span style='background:#FFA86D'>3rd</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Fairley</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Woodley</span> <span style='background:#DDDDDD'>D</span></span> et al</aug> (<span style='background:#66FF66'>2015</span>) <span style='background:#CCCCFF'>A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone</span>. <span style='background:#CCFF99'>Br J Dermatol</span> <span style='background:#FFCC66'>172</span>:<span style='background:#D279FF'>760&#8211;768</span></td><td><a href=http://dx.doi.org/10.1111/bjd.13350>10.1111/bjd.13350</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, JournalTitle, Year, FirstPage, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR30</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hammers</span> <span style='background:#DDDDDD'>CM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Chen</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lin</span> <span style='background:#DDDDDD'>C</span></span> et al</aug> (<span style='background:#66FF66'>2015</span>) <span style='background:#CCCCFF'>Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years</span>. <span style='background:#CCFF99'>J Invest Dermatol</span> <span style='background:#FFCC66'>135</span>:<span style='background:#D279FF'>742&#8211;749</span></td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1038/jid.2014.291>10.1038/jid.2014.291</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, FirstPage, Year, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR31</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Heizmann</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Itin</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wernli</span> <span style='background:#DDDDDD'>M</span></span> et al</aug> (<span style='background:#66FF66'>2001</span>) <span style='background:#CCCCFF'>Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL</span>. <span style='background:#CCFF99'>Am J Hematol</span> <span style='background:#FFCC66'>66</span>:<span style='background:#D279FF'>142&#8211;144</span></td><td><a href=http://dx.doi.org/10.1002/1096-8652(200102)66:2%3C142::AID-AJH1032%3E3.3.CO;2-S>10.1002/1096-8652(200102)66:2%3C142::AID-AJH1032%3E3.3.CO;2-S</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR32</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#FFFF80'>van der</span> <span style='background:#BCBCBC'>Helm</span> <span style='background:#DDDDDD'>LH</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bosman</span> <span style='background:#DDDDDD'>MC</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Schuringa</span> <span style='background:#DDDDDD'>JJ</span></span> et al</aug> (<span style='background:#66FF66'>2015</span>) <span style='background:#CCCCFF'>Effective trageting of primitive AML CD34+-cells by the second-generation proteasome inhibitor carfilzomib</span>. <span style='background:#CCFF99'>Br J Haematol</span> doi:<span style='background:#CFBFB1'>10.1111/bjh.13418</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hertl</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span></aug> (<span style='background:#66FF66'>2009</span>) <span style='background:#CCCCFF'>Pemphigus vulgaris</span>. <span style='background:#CCFF99'>CME Dermatol</span> <span style='background:#FFCC66'>4</span>:<span style='background:#D279FF'>94&#8211;115</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hertl</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Borradori</span> <span style='background:#DDDDDD'>L</span></span></aug> (<span style='background:#66FF66'>2007</span>) <span style='background:#CCCCFF'>Rituximab (anti-CD20 monoclonal antibody)&#8211;ultimate or first choice in pemphigus?</span> <span style='background:#CCFF99'>Dermatology</span> <span style='background:#FFCC66'>214</span>:<span style='background:#D279FF'>275&#8211;277</span></td><td><a href=http://dx.doi.org/10.1159/000100876>10.1159/000100876</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, FirstPage, Year, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR35</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hertl</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Veldman</span> <span style='background:#DDDDDD'>C</span></span></aug> (<span style='background:#66FF66'>2006</span>) <span style='background:#CCCCFF'>T cell control in autoimmune bullous skin disorders</span>. <span style='background:#CCFF99'>J Clin Invest</span> <span style='background:#FFCC66'>116</span>:<span style='background:#D279FF'>1159&#8211;1166</span></td><td><a href=http://dx.doi.org/10.1172/JCI28547>10.1172/JCI28547</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, Year, FirstPage, VolumeID</td><td>CrossRef</td></tr><tr><td>CR36</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hertl</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Zillikens</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Borradori</span> <span style='background:#DDDDDD'>L</span></span> et al</aug> (<span style='background:#66FF66'>2008</span>) <span style='background:#CCCCFF'>Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases</span>. <span style='background:#CCFF99'>J Dtsch Dermatol Ges</span> <span style='background:#FFCC66'>6</span>:<span style='background:#D279FF'>366&#8211;373</span></td><td><a href=http://dx.doi.org/10.1111/j.1610-0387.2007.06602.x>10.1111/j.1610-0387.2007.06602.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Year, FirstPage, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR37</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hoitsma</span> <span style='background:#DDDDDD'>AJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Woodle</span> <span style='background:#DDDDDD'>ES</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Abramowicz</span> <span style='background:#DDDDDD'>D</span></span> et al</aug> (<span style='background:#66FF66'>2011</span>) <span style='background:#CCCCFF'>FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study</span>. <span style='background:#CCFF99'>Nephrol Dial Transplant</span> <span style='background:#FFCC66'>26</span>:<span style='background:#D279FF'>3802&#8211;3805</span></td><td><a href=http://dx.doi.org/10.1093/ndt/gfr503>10.1093/ndt/gfr503</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Year, FirstPage, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR38</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hueber</span> <span style='background:#DDDDDD'>W</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Patel</span> <span style='background:#DDDDDD'>DD</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dryja</span> <span style='background:#DDDDDD'>T</span></span> et al</aug> (<span style='background:#66FF66'>2010</span>) <span style='background:#CCCCFF'>Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis</span>. <span style='background:#CCFF99'>Sci Transl Med</span> <span style='background:#FFCC66'>2</span>:<span style='background:#D279FF'>52&#8211;72</span></td><td><a href=http://dx.doi.org/10.1126/scitranslmed.3001107>10.1126/scitranslmed.3001107</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, VolumeID, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR39</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Jacobi</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Shuler</span> <span style='background:#DDDDDD'>G</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hertl</span> <span style='background:#DDDDDD'>M</span></span></aug> (<span style='background:#66FF66'>2005</span>) <span style='background:#CCCCFF'>Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab</span>. <span style='background:#CCFF99'>Br J Dermatol</span> <span style='background:#FFCC66'>153</span>:<span style='background:#D279FF'>448&#8211;449</span></td><td><a href=http://dx.doi.org/10.1111/j.1365-2133.2005.06744.x>10.1111/j.1365-2133.2005.06744.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, VolumeID, ArticleTitle, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR40</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Joly</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mouquet</span> <span style='background:#DDDDDD'>H</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Roujeau</span> <span style='background:#DDDDDD'>JC</span></span> et al</aug> (<span style='background:#66FF66'>2007</span>) <span style='background:#CCCCFF'>A single cycle of rituximab for the treatment of severe pemphigus</span>. <span style='background:#CCFF99'>N Engl J Med</span> <span style='background:#FFCC66'>357</span>:<span style='background:#D279FF'>545&#8211;552</span></td><td><a href=http://dx.doi.org/10.1056/NEJMoa067752>10.1056/NEJMoa067752</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR41</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kasperkiewicz</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Behzad</span> <span style='background:#DDDDDD'>M</span></span> et al</aug> (<span style='background:#66FF66'>2012</span>) <span style='background:#CCCCFF'>Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases</span>. <span style='background:#CCFF99'>J Dtsch Dermatol Ges</span> <span style='background:#FFCC66'>10</span>:<span style='background:#D279FF'>727&#8211;732</span></td><td><a href=http://dx.doi.org/10.1111/j.1610-0387.2012.07931.x>10.1111/j.1610-0387.2012.07931.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Year, FirstPage, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR42</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kaur</span> <span style='background:#DDDDDD'>K</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kalra</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kaushal</span> <span style='background:#DDDDDD'>S</span></span></aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Systemic review of tofacitinib: a new drug for the management of rheumatoid arthritis</span>. <span style='background:#CCFF99'>Clin Ther</span> <span style='background:#FFCC66'>36</span>:<span style='background:#D279FF'>1074&#8211;1086</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR43</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kneisel</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hertl</span> <span style='background:#DDDDDD'>M</span></span></aug> (<span style='background:#66FF66'>2011</span>) <span style='background:#CCCCFF'>Autoimmune bullous skin diseases. Part 1: clinical manifestations</span>. <span style='background:#CCFF99'>J Dtsch Dermatol Ges</span> <span style='background:#FFCC66'>9</span>:<span style='background:#D279FF'>844&#8211;856</span></td><td><a href=http://dx.doi.org/10.1111/j.1610-0387.2011.07793.x>10.1111/j.1610-0387.2011.07793.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, VolumeID, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR44</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Knier</span> <span style='background:#DDDDDD'>B</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hemmer</span> <span style='background:#DDDDDD'>B</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Korn</span> <span style='background:#DDDDDD'>T</span></span></aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Novel monoclonal antibodies for therapy of multiple sclerosis</span>. <span style='background:#CCFF99'>Expert Opin Biol Ther</span> <span style='background:#FFCC66'>14</span>:<span style='background:#D279FF'>503&#8211;513</span></td><td><a href=http://dx.doi.org/10.1517/14712598.2014.887676>10.1517/14712598.2014.887676</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR45</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kwon</span> <span style='background:#DDDDDD'>EJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Yamagami</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Nishikawa</span> <span style='background:#DDDDDD'>T</span></span> et al</aug> (<span style='background:#66FF66'>2008</span>) <span style='background:#CCCCFF'>Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission</span>. <span style='background:#CCFF99'>J Eur Acad Dermatol Venereol</span> <span style='background:#FFCC66'>22</span>:<span style='background:#D279FF'>1070&#8211;1075</span></td><td><a href=http://dx.doi.org/10.1111/j.1468-3083.2008.02715.x>10.1111/j.1468-3083.2008.02715.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR46</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Langley</span> <span style='background:#DDDDDD'>RG</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Elewski</span> <span style='background:#DDDDDD'>BE</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lebwohl</span> <span style='background:#DDDDDD'>M</span></span> et al</aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Secukinumab in plaque psoriasis &#8211; results of two phase 3 trials</span>. <span style='background:#CCFF99'>N Engl J Med</span> <span style='background:#FFCC66'>371</span>:<span style='background:#D279FF'>326&#8211;338</span></td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1314258>10.1056/NEJMoa1314258</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR47</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Li</span> <span style='background:#DDDDDD'>N</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Zhao</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hilario-Vargas</span> <span style='background:#DDDDDD'>J</span></span> et al</aug> (<span style='background:#66FF66'>2005</span>) <span style='background:#CCCCFF'>Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases</span>. <span style='background:#CCFF99'>J Clin Invest</span> <span style='background:#FFCC66'>115</span>:<span style='background:#D279FF'>3440&#8211;3450</span></td><td><a href=http://dx.doi.org/10.1172/JCI24394>10.1172/JCI24394</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, VolumeID, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR48</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>L&#252;ftl</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Stauber</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mainka</span> <span style='background:#DDDDDD'>A</span></span> et al</aug> (<span style='background:#66FF66'>2003</span>) <span style='background:#CCCCFF'>Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber</span>. <span style='background:#CCFF99'>Br J Dermatol</span> <span style='background:#FFCC66'>149</span>:<span style='background:#D279FF'>598&#8211;605</span></td><td><a href=http://dx.doi.org/10.1046/j.1365-2133.2003.05513.x>10.1046/j.1365-2133.2003.05513.x</a></td><td>&nbsp;</td><td><b>CrossRef-Web</b></td>
<td>VolumeID, Author_FamilyName_2, Year, FirstPage, JournalTitle, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR49</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lunardon</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Payne</span> <span style='background:#DDDDDD'>AS</span></span></aug> (<span style='background:#66FF66'>2012</span>) <span style='background:#CCCCFF'>Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus</span>. <span style='background:#CCFF99'>J Allergy Clin Immunol</span> <span style='background:#FFCC66'>130</span>:<span style='background:#D279FF'>800&#8211;803</span></td><td><a href=http://dx.doi.org/10.1016/j.jaci.2012.03.022>10.1016/j.jaci.2012.03.022</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR50</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lunardon</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Payne</span> <span style='background:#DDDDDD'>AS</span></span></aug> (<span style='background:#66FF66'>2012</span>) <span style='background:#CCCCFF'>Rituximab for autoimmune blistering diseases: recent studies, new insights</span>. <span style='background:#CCFF99'>G Ital Dermatol Venereol</span> <span style='background:#FFCC66'>147</span>:<span style='background:#D279FF'>269&#8211;276</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR51</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lunardon</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Tsai</span> <span style='background:#DDDDDD'>KJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Propert</span> <span style='background:#DDDDDD'>KJ</span></span> et al</aug> (<span style='background:#66FF66'>2012</span>) <span style='background:#CCCCFF'>Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients</span>. <span style='background:#CCFF99'>Arch Dermatol</span> <span style='background:#FFCC66'>148</span>:<span style='background:#D279FF'>1031&#8211;1036</span></td><td><a href=http://dx.doi.org/10.1001/archdermatol.2012.1522>10.1001/archdermatol.2012.1522</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, Year, ArticleTitle, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR52</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lutterotti</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Yousef</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sputtek</span> <span style='background:#DDDDDD'>A</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#FFD9B3'>Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis</span> . Sci Trans Med 5:188ra75</td><td><a href=http://dx.doi.org/10.1126/scitranslmed.3006168>10.1126/scitranslmed.3006168</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, Author_FamilyName_1, BookTitle</td><td>CrossRef</td></tr><tr><td>CR53</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mariette</span> <span style='background:#DDDDDD'>X</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Seror</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Quartuccio</span> <span style='background:#DDDDDD'>L</span></span> et al</aug> (<span style='background:#66FF66'>2015</span>) <span style='background:#CCCCFF'>Efficacy and safety of belimumab in primary Sj&#246;gren's syndrome: results of the BELISS open-label phase II study</span>. <span style='background:#CCFF99'>Ann Rheum Dis</span> <span style='background:#FFCC66'>74</span>:<span style='background:#D279FF'>526&#8211;531</span></td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1136/annrheumdis-2013-203991>10.1136/annrheumdis-2013-203991</a></td><td><b>CrossRef-Web</b></td>
<td>VolumeID, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR54</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mease</span> <span style='background:#DDDDDD'>PJ</span></span></aug> (<span style='background:#66FF66'>2015</span>) <span style='background:#CCCCFF'>Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis</span>. <span style='background:#CCFF99'>Curr Opin Rheumatol</span> <span style='background:#FFCC66'>27</span>:<span style='background:#D279FF'>127&#8211;133</span></td><td><a href=http://dx.doi.org/10.1097/BOR.0000000000000147>10.1097/BOR.0000000000000147</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, FirstPage, Year, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR55</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Merrill</span> <span style='background:#DDDDDD'>JT</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Burgos-Vargas</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Westhovens</span> <span style='background:#DDDDDD'>R</span></span> et al</aug> (<span style='background:#66FF66'>2010</span>) <span style='background:#CCCCFF'>The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of twelve-month, multicenter, exploratory phase IIb, randomized, double-blind, placebo-controlled trial</span>. <span style='background:#CCFF99'>Arthritis Rheum</span> <span style='background:#FFCC66'>62</span>:<span style='background:#D279FF'>3077&#8211;3087</span></td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/art.27601>10.1002/art.27601</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, FirstPage, Year, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR56</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Meurer</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Braun-Falco</span> <span style='background:#DDDDDD'>O</span></span></aug> (<span style='background:#66FF66'>1979</span>) <span style='background:#CCCCFF'>Plasma exchange in the treatment of pemphigus vulgaris</span>. <span style='background:#CCFF99'>Br J Dermatol</span> <span style='background:#FFCC66'>100</span>:<span style='background:#D279FF'>231&#8211;232</span></td><td><a href=http://dx.doi.org/10.1111/j.1365-2133.1979.tb05571.x>10.1111/j.1365-2133.1979.tb05571.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, FirstPage, Year, ArticleTitle, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR57</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Nagel</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hertl</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span></aug> (<span style='background:#66FF66'>2009</span>) <span style='background:#CCCCFF'>B-cell-directed therapy for inflammatory skin diseases</span>. <span style='background:#CCFF99'>J Invest Dermatol</span> <span style='background:#FFCC66'>129</span>:<span style='background:#D279FF'>289&#8211;301</span></td><td><a href=http://dx.doi.org/10.1038/jid.2008.192>10.1038/jid.2008.192</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR58</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Nagel</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Podstawa</span> <span style='background:#DDDDDD'>E</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eickmann</span> <span style='background:#DDDDDD'>M</span></span> et al</aug> (<span style='background:#66FF66'>2009</span>) <span style='background:#CCCCFF'>Rituximab mediates a strong elevation of B-cellactivating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris</span>. <span style='background:#CCFF99'>J Invest Dermatol</span> <span style='background:#FFCC66'>129</span>:<span style='background:#D279FF'>2202&#8211;2210</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR59</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Narbutt</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Lukamowicz</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bogaczewicz</span> <span style='background:#DDDDDD'>J</span></span> et al</aug> (<span style='background:#66FF66'>2008</span>) <span style='background:#FFD9B3'>Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris</span> . Mediatros Inflamm doi:<span style='background:#CFBFB1'>10.1155/2008/875394</span></td><td><a href=http://dx.doi.org/10.1155/2008/875394>10.1155/2008/875394</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, BookTitle, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR60</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Navarra</span> <span style='background:#DDDDDD'>SV</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Guzman</span> <span style='background:#DDDDDD'>RM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gallacher</span> <span style='background:#DDDDDD'>AE</span></span> et al</aug> (<span style='background:#66FF66'>2011</span>) <span style='background:#CCCCFF'>Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial</span>. <span style='background:#CCFF99'>Lancet</span> <span style='background:#FFCC66'>377</span>:<span style='background:#D279FF'>721&#8211;731</span></td><td><a href=http://dx.doi.org/10.1016/S0140-6736(10)61354-2>10.1016/S0140-6736(10)61354-2</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, Year, FirstPage, VolumeID</td><td>CrossRef</td></tr><tr><td>CR61</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Nigrovic</span> <span style='background:#DDDDDD'>PA</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mannion</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Prince</span> <span style='background:#DDDDDD'>FH</span></span> et al</aug> (<span style='background:#66FF66'>2011</span>) <span style='background:#CCCCFF'>Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series</span>. <span style='background:#CCFF99'>Arthritis Rheum</span> <span style='background:#FFCC66'>63</span>:<span style='background:#D279FF'>545&#8211;555</span></td><td><a href=http://dx.doi.org/10.1002/art.30128>10.1002/art.30128</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, Year, FirstPage, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR62</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#FFFF80'>de</span> <span style='background:#BCBCBC'>Paoli</span> <span style='background:#DDDDDD'>FV</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Nielsen</span> <span style='background:#DDDDDD'>BD</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Rasmussen</span> <span style='background:#DDDDDD'>F</span></span> et al</aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Abatacept induces clinical improvement in patients with severe systemic sclerosis</span>. <span style='background:#CCFF99'>Scand J Rheumatol</span> <span style='background:#FFCC66'>43</span>:<span style='background:#D279FF'>342&#8211;345</span></td><td><a href=http://dx.doi.org/10.3109/03009742.2013.812238>10.3109/03009742.2013.812238</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Author_FamilyName_2, VolumeID, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR63</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Pardo</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mercader</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mahiques</span> <span style='background:#DDDDDD'>L</span></span> et al</aug> (<span style='background:#66FF66'>2005</span>) <span style='background:#CCCCFF'>Infliximab in the management of severe pemphigus vulgaris</span>. <span style='background:#CCFF99'>Br J Dermatol</span> <span style='background:#FFCC66'>153</span>:<span style='background:#D279FF'>222&#8211;223</span></td><td><a href=http://dx.doi.org/10.1111/j.1365-2133.2005.06672.x>10.1111/j.1365-2133.2005.06672.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, JournalTitle, Year, FirstPage, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR64</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Payne</span> <span style='background:#DDDDDD'>AS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hanakawa</span> <span style='background:#DDDDDD'>Y</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Amagai</span> <span style='background:#DDDDDD'>M</span></span> et al</aug> (<span style='background:#66FF66'>2004</span>) <span style='background:#CCCCFF'>Desmosomes and disease: pemphigus and bullous impetigo</span>. <span style='background:#CCFF99'>Curr Opin Cell Biol</span> <span style='background:#FFCC66'>16</span>:<span style='background:#D279FF'>536&#8211;543</span></td><td><a href=http://dx.doi.org/10.1016/j.ceb.2004.07.006>10.1016/j.ceb.2004.07.006</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, VolumeID, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR65</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Pfutze</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kneisel</span> <span style='background:#DDDDDD'>A</span></span> et al</aug> (<span style='background:#66FF66'>2009</span>) <span style='background:#CCCCFF'>Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab</span>. <span style='background:#CCFF99'>Dermatology</span> <span style='background:#FFCC66'>218</span>:<span style='background:#D279FF'>237&#8211;245</span></td><td><a href=http://dx.doi.org/10.1159/000187431>10.1159/000187431</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, ArticleTitle, VolumeID, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR66</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Rizzo</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Fotino</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Zhang</span> <span style='background:#DDDDDD'>Y</span></span> et al</aug> (<span style='background:#66FF66'>2005</span>) <span style='background:#CCCCFF'>Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease</span>. <span style='background:#CCFF99'>Clin Exp Dermatol</span> <span style='background:#FFCC66'>30</span>:<span style='background:#D279FF'>535&#8211;540</span></td><td><a href=http://dx.doi.org/10.1111/j.1365-2230.2005.01836.x>10.1111/j.1365-2230.2005.01836.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, FirstPage, Year, ArticleTitle, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR67</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ruperto</span> <span style='background:#DDDDDD'>N</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Brunner</span> <span style='background:#DDDDDD'>HI</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Quartier</span> <span style='background:#DDDDDD'>P</span></span> et al</aug> (<span style='background:#66FF66'>2012</span>) <span style='background:#CCCCFF'>Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis</span>. <span style='background:#CCFF99'>N Engl J Med</span> <span style='background:#FFCC66'>367</span>:<span style='background:#D279FF'>2396&#8211;2406</span></td><td><a href=http://dx.doi.org/10.1056/NEJMoa1205099>10.1056/NEJMoa1205099</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR68</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sardy</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kasperkiewicz</span> <span style='background:#DDDDDD'>M</span></span></aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Bullous autoimmune disorders in children</span>. <span style='background:#CCFF99'>Hautarzt</span> <span style='background:#FFCC66'>64</span>:<span style='background:#D279FF'>447&#8211;455</span></td><td><a href=http://dx.doi.org/10.1007/s00105-013-2536-y>10.1007/s00105-013-2536-y</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Schmidt</span> <span style='background:#DDDDDD'>E</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Klinker</span> <span style='background:#DDDDDD'>E</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Opitz</span> <span style='background:#DDDDDD'>A</span></span> et al</aug> (<span style='background:#66FF66'>2003</span>) <span style='background:#CCCCFF'>Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus</span>. <span style='background:#CCFF99'>Br J Dermatol</span> <span style='background:#FFCC66'>148</span>:<span style='background:#D279FF'>1222&#8211;1229</span></td><td><a href=http://dx.doi.org/10.1046/j.1365-2133.2003.05302.x>10.1046/j.1365-2133.2003.05302.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, Author_FamilyName_2, VolumeID, Author_FamilyName_1, JournalTitle, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR70</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Schmidt</span> <span style='background:#DDDDDD'>E</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hennig</span> <span style='background:#DDDDDD'>K</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Mengede</span> <span style='background:#DDDDDD'>C</span></span> et al</aug> (<span style='background:#66FF66'>2009</span>) <span style='background:#CCCCFF'>Immunogenicity of rituximab in patients with severe pemphigus</span>. <span style='background:#CCFF99'>Clin Immunol</span> <span style='background:#FFCC66'>132</span>:<span style='background:#D279FF'>334&#8211;341</span></td><td><a href=http://dx.doi.org/10.1016/j.clim.2009.05.007>10.1016/j.clim.2009.05.007</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, Year, FirstPage, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR71</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Seidling</span> <span style='background:#DDDDDD'>V</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hoffmann</span> <span style='background:#DDDDDD'>JH</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Enk</span> <span style='background:#DDDDDD'>AH</span></span>, et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events</span>. <span style='background:#CCFF99'>Acta Derm Venereol</span> <span style='background:#FFCC66'>93</span>:<span style='background:#D279FF'>346&#8211;349</span></td><td><a href=http://dx.doi.org/10.2340/00015555-1471>10.2340/00015555-1471</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, FirstPage, Year, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR72</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Shimanovich</span> <span style='background:#DDDDDD'>I</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Herzog</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Schmidt</span> <span style='background:#DDDDDD'>E</span></span> et al</aug> (<span style='background:#66FF66'>2006</span>) <span style='background:#CCCCFF'>Improved protocol for treatment of pemphigus vulgaris with protein a immunoadsorption</span>. <span style='background:#CCFF99'>Clin Exp Dermatol</span> <span style='background:#FFCC66'>31</span>:<span style='background:#D279FF'>768&#8211;774</span></td><td><a href=http://dx.doi.org/10.1111/j.1365-2230.2006.02220.x>10.1111/j.1365-2230.2006.02220.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Year, FirstPage, JournalTitle, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR73</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Spindler</span> <span style='background:#DDDDDD'>V</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>R&#246;tzer</span> <span style='background:#DDDDDD'>V</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dehner</span> <span style='background:#DDDDDD'>C</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering</span>. <span style='background:#CCFF99'>J Clin Invest</span> <span style='background:#FFCC66'>123</span>:<span style='background:#D279FF'>800&#8211;811</span></td><td><a href=http://dx.doi.org/10.1172/JCI60139>10.1172/JCI60139</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR74</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Steinfeld</span> <span style='background:#DDDDDD'>SD</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Youinou</span> <span style='background:#DDDDDD'>P</span></span></aug> (<span style='background:#66FF66'>2006</span>) <span style='background:#CCCCFF'>Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases</span>. <span style='background:#CCFF99'>Expert Opin Biol Ther</span> <span style='background:#FFCC66'>6</span>:<span style='background:#D279FF'>943&#8211;949</span></td><td><a href=http://dx.doi.org/10.1517/14712598.6.9.943>10.1517/14712598.6.9.943</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, Year, FirstPage, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR75</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Stohl</span> <span style='background:#DDDDDD'>W</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Merrill</span> <span style='background:#DDDDDD'>JT</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>McKay</span> <span style='background:#DDDDDD'>JD</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study</span>. <span style='background:#CCFF99'>J Rheumatol</span> <span style='background:#FFCC66'>40</span>:<span style='background:#D279FF'>579&#8211;589</span></td><td><a href=http://dx.doi.org/10.3899/jrheum.120886>10.3899/jrheum.120886</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Author_FamilyName_2, VolumeID, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR76</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Toosi</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Habib</span> <span style='background:#DDDDDD'>N</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Torres</span> <span style='background:#DDDDDD'>G</span></span> et al</aug> (<span style='background:#66FF66'>2011</span>) <span style='background:#CCCCFF'>Serum levels of inhibitors of apoptotic proteins (IAPs) change with IVIg therapy in pemphigus</span>. <span style='background:#CCFF99'>J Invest Dermatol</span> <span style='background:#FFCC66'>131</span>:<span style='background:#D279FF'>2327&#8211;2329</span></td><td><a href=http://dx.doi.org/10.1038/jid.2011.184>10.1038/jid.2011.184</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Author_FamilyName_2, VolumeID, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR77</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Veldman</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Hohne</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dieckmann</span> <span style='background:#DDDDDD'>D</span></span> et al</aug> (<span style='background:#66FF66'>2004</span>) <span style='background:#CCCCFF'>Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris</span>. <span style='background:#CCFF99'>J Immunol</span> <span style='background:#FFCC66'>172</span>:<span style='background:#D279FF'>6468&#8211;6475</span></td><td><a href=http://dx.doi.org/10.4049/jimmunol.172.10.6468>10.4049/jimmunol.172.10.6468</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, Year, FirstPage, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR78</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wallace</span> <span style='background:#DDDDDD'>DJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gordon</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Strand</span> <span style='background:#DDDDDD'>V</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Efficacy and safety of epratuzumab in patients with moderate/flaring systemic lupus erythematosus: results of two randomied, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up</span>. <span style='background:#CCFF99'>Rheumatology</span> <span style='background:#FFCC66'>52</span>:<span style='background:#D279FF'>1313&#8211;1322</span></td><td><a href=http://dx.doi.org/10.1093/rheumatology/ket129>10.1093/rheumatology/ket129</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, FirstPage, Year, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR79</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wenzel</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ford</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Pearlman</span> <span style='background:#DDDDDD'>D</span></span> et al</aug> (<span style='background:#66FF66'>2013</span>) <span style='background:#CCCCFF'>Dupilumab in persistent asthma with elevated eosinophil levels</span>. <span style='background:#CCFF99'>N Engl J Med</span> <span style='background:#FFCC66'>368</span>:<span style='background:#D279FF'>2455&#8211;2466</span></td><td><a href=http://dx.doi.org/10.1056/NEJMoa1304048>10.1056/NEJMoa1304048</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Xing</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dai</span> <span style='background:#DDDDDD'>Z</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Jabbari</span> <span style='background:#DDDDDD'>A</span></span> et al</aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition</span>. <span style='background:#CCFF99'>Nat Med</span> <span style='background:#FFCC66'>20</span>:<span style='background:#D279FF'>1043&#8211;1049</span></td><td><a href=http://dx.doi.org/10.1038/nm.3645>10.1038/nm.3645</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR81</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Yokoyama</span> <span style='background:#DDDDDD'>T</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Amagai</span> <span style='background:#DDDDDD'>M</span></span></aug> (<span style='background:#66FF66'>2010</span>) <span style='background:#CCCCFF'>Immune dysregulation of pemphigus in humans and mice</span>. <span style='background:#CCFF99'>J Dermatol</span> <span style='background:#FFCC66'>37</span>:<span style='background:#D279FF'>205&#8211;213</span></td><td><a href=http://dx.doi.org/10.1111/j.1346-8138.2009.00797.x>10.1111/j.1346-8138.2009.00797.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR82</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Zillikens</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Derfler</span> <span style='background:#DDDDDD'>K</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eming</span> <span style='background:#DDDDDD'>R</span></span> et al</aug> (<span style='background:#66FF66'>2007</span>) <span style='background:#CCCCFF'>Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases</span>. <span style='background:#CCFF99'>J Dtsch Dermatol Ges</span> <span style='background:#FFCC66'>5</span>:<span style='background:#D279FF'>881&#8211;887</span></td><td><a href=http://dx.doi.org/10.1111/j.1610-0387.2007.06342.x>10.1111/j.1610-0387.2007.06342.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr></table>